Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $417,515.74 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 673 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $620.38, for a total transaction of $417,515.74. Following the transaction, the chief executive officer directly owned 544,544 shares of the company’s stock, valued at approximately $337,824,206.72. This represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Price Performance

MEDP stock opened at $600.65 on Friday. The stock has a market capitalization of $16.77 billion, a price-to-earnings ratio of 35.21, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The company has a 50-day moving average of $565.33 and a two-hundred day moving average of $494.55. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the previous year, the company posted $3.10 earnings per share. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Truist Financial upped their target price on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, BMO Capital Markets raised their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its stake in Medpace by 53,619.6% in the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after buying an additional 13,963,607 shares in the last quarter. BlackRock Inc. bought a new position in shares of Medpace during the second quarter valued at $1,323,047,000. AQR Capital Management LLC boosted its stake in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.